NL-OMON37697已完成不适用
A prospective, single arm feasibility study to evaluate the safety and performance of the SMT Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) - DEFLECT I Trial
SMT Medical Technologies0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.1 The patient must be >= 18 years of age.
- •1.2 The patient meets indications for TAVR procedure.
- •1.3 The patient is willing to comply with specified follow-up evaluations.
- •1.4 The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).
排除标准
- •2.1 Patients undergoing TAVR via the trans-axillary, subclavian or direct aortic route.
- •2.2 Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.
- •2.3 Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (according to definition) or AMI > 72 hours preceding the index procedure and CK and CK-MB have not returned to normal limits at the time of procedure
- •2.4 Patients who are currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain.
- •2.5 Patients with impaired renal function (estimated Glomerular Filtration Rate [eGFR] <30, calculated from serum creatinine by the Cockcroft-Gault formula).
- •2.6 Patients with a platelet count <100.000 cells/mm³ or >700.000 cells/mm³ or a WBC <3000 cells/mm³ within 7 days prior to index procedure.
- •2.7 Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or will refuse transfusion.
- •2.8 Patients who have received any organ transplant or are on a waiting list for any organ transplant.
- •2.9 Patients with known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a life expectancy of less than one year.
- •2.10 Patients with a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated.
- •2.11 Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months.
- •2.12 Patients with an active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.
- •2.13 Patients presenting with cardiogenic shock.
- •2.14 Patients with severe peripheral arterial disease that precludes 9Fr sheath vascular access.
- •2.15 Patients with documented friable or mobile atherosclerotic plaque in the aortic arch.
- •2.16 Patients with contraindication to cerebral MRI.
- •2.17 Patients who have a planned treatment with any other investigational device or procedure during the study period.
研究者
相似试验
进行中（未招募）
不适用
An evaluation of an online pain management programmeISRCTN11752770My Pain Ltd15
招募中
不适用
Prospective, single-centre, feasibility study to evaluate the use of 18F-PSMA PET/CT in patients with biochemically active medullary thyroid cancer.Medullary thyroid cancer10043739thyroid cancerNL-OMON51749niversitair Medisch Centrum Groningen15
已完成
2 期
A prospective, single arm feasibility pilot study to evaluate the safety and performance of the TriGuard*-HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)brain infarction10046973strokeNL-OMON40150Keystone Heart15
已完成
不适用
A prospective, single arm feasibility pilot study to evaluate the safety and performance of the TriGUARD*3 Embolic Protection Device in patients undergoing Transcatheter Aortic Valve Implantation (TAVI)Preventie CVA/TIA bij TAVIparalysis10046973StrokeNL-OMON46441Keystone Heart10
尚未招募
2 期
Dose-Dense ABVD Study: An accelerated delivery of Adriamycin, Bleomycin, Vinblastin and Dacarbazine for patients with Hodgkin LymphomaEarly Stage Unfavourable Hodgkin LymphomaAdvanced Stage Hodgkin LymphomaCancer - Hodgkin'sACTRN12612000137897Queensland Health31